Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches

This white paper examines recent progress, applications, and challenges in predicting unbound and total tissue and intra/subcellular drug concentrations using in vitro and preclinical models, imaging techniques, and physiologically based pharmacokinetic (PBPK) modeling. Published examples, regulatory submissions, and case studies illustrate the application of different types of data in drug development to support modeling and decision making for compounds with transporter‐mediated disposition, and likely disconnects between tissue and systemic drug exposure. The goals of this article are to illustrate current best practices and outline practical strategies for selecting appropriate in vitro and in vivo experimental methods to estimate or predict tissue and plasma concentrations, and to use these data in the application of PBPK modeling for human pharmacokinetic (PK), efficacy, and safety assessment in drug development.

[1]  Li Wang,et al.  Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics , 2016, Drug Metabolism and Disposition.

[2]  I. Anderson Understanding the processes , 2020 .

[3]  S. L. Goss,et al.  Effect of Ritonavir on 99mTechnetium–Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs , 2013, CPT: pharmacometrics & systems pharmacology.

[4]  K. Brouwer,et al.  Determination of Intracellular Unbound Concentrations and Subcellular Localization of Drugs in Rat Sandwich-Cultured Hepatocytes Compared with Liver Tissue , 2013, Drug Metabolism and Disposition.

[5]  T. Maurer,et al.  Toward a Unified Model of Passive Drug Permeation II: The Physiochemical Determinants of Unbound Tissue Distribution with Applications to the Design of Hepatoselective Glucokinase Activators , 2014, Drug Metabolism and Disposition.

[6]  S. Doblas,et al.  Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis , 2017, European Radiology.

[7]  Malcolm Rowland,et al.  Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.

[8]  Y. Sugiyama,et al.  Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG‐CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism , 2013, Clinical pharmacology and therapeutics.

[9]  Kazuya Maeda,et al.  PET Imaging–Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me , 2012, The Journal of Nuclear Medicine.

[10]  K Rowland-Yeo,et al.  Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  J. Manro,et al.  Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein , 2014, Drug Metabolism and Disposition.

[12]  X. Chu,et al.  Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development , 2014, Drug Metabolism and Disposition.

[13]  J. Huwyler,et al.  Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations , 2017, Drug Metabolism and Disposition.

[14]  L. Di,et al.  Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes , 2017, Drug Metabolism and Disposition.

[15]  M. Danhof,et al.  Prediction of human CNS pharmacokinetics using a physiologically‐based pharmacokinetic modeling approach , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  Neil Woodhouse,et al.  Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition , 2013, NMR in biomedicine.

[17]  M. Jamei,et al.  A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine , 2013, Clinical Pharmacokinetics.

[18]  Jashvant D Unadkat,et al.  Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the Model for Passive Placental Permeability Drugs , 2017, Drug Metabolism and Disposition.

[19]  Nikolaos Tsamandouras,et al.  Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk , 2014, Pharmaceutical Research.

[20]  W. Löscher,et al.  Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood–Brain Barrier , 2016, Clinical pharmacology and therapeutics.

[21]  C. Battista,et al.  Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters , 2017, Clinical pharmacology and therapeutics.

[22]  Yingying Guo,et al.  Ethnic Variability in the Expression of Hepatic Drug Transporters: Absolute Quantification by an Optimized Targeted Quantitative Proteomic Approach , 2015, Drug Metabolism and Disposition.

[23]  M. Hann,et al.  Direct Measurement of Intracellular Compound Concentration by RapidFire Mass Spectrometry Offers Insights into Cell Permeability , 2016, Journal of biomolecular screening.

[24]  T. Lavé,et al.  A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.

[25]  J. Huwyler,et al.  Current In Vitro Methods to Determine Hepatic Kpuu: A Comparison of Their Usefulness and Limitations. , 2017, Journal of pharmaceutical sciences.

[26]  P. Artursson,et al.  A High-Throughput Cell-Based Method to Predict the Unbound Drug Fraction in the Brain , 2014, Journal of medicinal chemistry.

[27]  P. Lamy Drug Disposition and Pharmacokinetics , 1977 .

[28]  Yasuyoshi Watanabe,et al.  Evaluation of Breast Cancer Resistance Protein Function in Hepatobiliary and Renal Excretion Using PET with 11C-SC-62807 , 2013, The Journal of Nuclear Medicine.

[29]  M. Varma,et al.  Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters , 2017, Clinical pharmacology and therapeutics.

[30]  P. Artursson,et al.  Intracellular drug bioavailability: a new predictor of system dependent drug disposition , 2017, Scientific Reports.

[31]  A. McIntosh,et al.  FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein. , 2016, Biochemistry.

[32]  D. Mankoff,et al.  Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.

[33]  J. Wiśniewski,et al.  Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes. , 2017, Molecular pharmaceutics.

[34]  Kazuya Maeda,et al.  Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. , 2013, Biopharmaceutics & drug disposition.

[35]  Yuichi Sugiyama,et al.  Quantitative Evaluation of mMate1 Function Based on Minimally Invasive Measurement of Tissue Concentration Using PET with [11C]Metformin in Mouse , 2015, Pharmaceutical Research.

[36]  O. Langer Use of PET Imaging to Evaluate Transporter‐Mediated Drug‐Drug Interactions , 2016, Journal of clinical pharmacology.

[37]  Maria M. Posada,et al.  Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib , 2017, Clinical and translational science.

[38]  C. Vanhove,et al.  Synthesis, in vitro and in vivo small-animal SPECT evaluation of novel technetium labeled bile acid analogues to study (altered) hepatic transporter function. , 2016, Nuclear medicine and biology.

[39]  K. Giacomini,et al.  The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin , 2016, Clinical Pharmacokinetics.

[40]  D. Tibboel,et al.  Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics , 2015, Clinical Pharmacokinetics.

[41]  Amin Rostami‐Hodjegan,et al.  Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence , 2017, Clinical pharmacology and therapeutics.

[42]  Ming-Rong Zhang,et al.  Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. , 2017, Journal of pharmaceutical sciences.

[43]  Y. Sugiyama,et al.  Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver , 2013, Clinical pharmacology and therapeutics.

[44]  Aleksandra Galetin,et al.  Incorporation of lysosomal sequestration in the mechanistic model for prediction of tissue distribution of basic drugs , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[45]  Yurong Lai,et al.  Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs* , 2004, Journal of Biological Chemistry.

[46]  Shiew-Mei Huang,et al.  Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction. , 2017, Journal of pharmaceutical sciences.

[47]  M Jamei,et al.  ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans , 2013, Clinical pharmacology and therapeutics.

[48]  J. G. Kenna,et al.  In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.

[49]  A. Galetin,et al.  Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[50]  Drugs interacting with organic anion transporter-1 affect uptake of Tc-99m-mercaptoacetyl-triglycine (MAG3) in the human kidney: therapeutic drug interaction in Tc-99m-MAG3 diagnosis of renal function and possible application of Tc-99m-MAG3 for drug development. , 2013, Nuclear medicine and biology.

[51]  S. Jakobsen,et al.  Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans , 2017, Clinical pharmacology and therapeutics.

[52]  Peter Lundberg,et al.  Physiologically Realistic and Validated Mathematical Liver Model Revels Hepatobiliary Transfer Rates for Gd-EOB-DTPA Using Human DCE-MRI Data , 2014, PloS one.

[53]  Leon Aarons,et al.  Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach , 2014, Pharmaceutical Research.

[54]  J. Unadkat,et al.  Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides , 2018, Drug Metabolism and Disposition.

[55]  J. Unadkat,et al.  Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model , 2016, Clinical pharmacology and therapeutics.

[56]  Michael Gertz,et al.  In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. , 2017, Molecular pharmaceutics.

[57]  A. Galetin,et al.  In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383 , 2015, Pharmaceutical Research.

[58]  J. Houston,et al.  Understanding the Interplay Between Uptake and Efflux Transporters Within In Vitro Systems in Defining Hepatocellular Drug Concentrations. , 2017, Journal of pharmaceutical sciences.

[59]  Yuan Chen,et al.  Strategies of Drug Transporter Quantitation by LC-MS: Importance of Peptide Selection and Digestion Efficiency , 2017, The AAPS Journal.

[60]  Maria M. Posada,et al.  Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling , 2015, Drug Metabolism and Disposition.

[61]  Lei Zhang,et al.  Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations , 2014, Clinical Pharmacokinetics.

[62]  Murat Cirit,et al.  Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies , 2018, Scientific Reports.

[63]  D. Shapiro,et al.  Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage , 2016, Clinical and translational science.

[64]  R. Cecchelli,et al.  A Simple Method for Assessing Free Brain/Free Plasma Ratios Using an In Vitro Model of the Blood Brain Barrier , 2013, PloS one.

[65]  D. Shlaes,et al.  A Pharmaceutical Industry Perspective , 2004 .

[66]  O. van Tellingen,et al.  Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. , 2015, Molecular pharmaceutics.

[67]  A. Galetin,et al.  Novel Methodology for the Isolation of Lysosomes and Measurement of Intralysosomal Drug Accumulation , 2017 .

[68]  K. Brouwer,et al.  Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors? , 2017, Journal of pharmaceutical sciences.

[69]  S. Neuhoff,et al.  Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis , 2016, Drug Metabolism and Disposition.

[70]  Y. Sugiyama,et al.  Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologica , 2017, Journal of pharmaceutical sciences.

[71]  P. Jasper,et al.  Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1–Transfected Human Embryonic Kidney 293 Cells , 2016, Drug Metabolism and Disposition.

[72]  Aleksandra Galetin,et al.  Meta-Analysis of Expression of Hepatic Organic Anion–Transporting Polypeptide (OATP) Transporters in Cellular Systems Relative to Human Liver Tissue , 2015, Drug Metabolism and Disposition.

[73]  J. Wiśniewski,et al.  Comparative Proteomic Analysis of Human Liver Tissue and Isolated Hepatocytes with a Focus on Proteins Determining Drug Exposure. , 2015, Journal of proteome research.

[74]  D. Mankoff,et al.  Regional P‐Glycoprotein Activity and Inhibition at the Human Blood–Brain Barrier as Imaged by Positron Emission Tomography , 2010, Clinical pharmacology and therapeutics.

[75]  David A Mankoff,et al.  Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study , 2015, Drug Metabolism and Disposition.

[76]  Elevated Basal Ganglia Glucose Metabolism in Cyclosporine Neurotoxicity: A Positron Emission Tomography Imaging Study , 2002, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[77]  Per Artursson,et al.  Rapid measurement of intracellular unbound drug concentrations. , 2013, Molecular pharmaceutics.

[78]  F. O’Sullivan,et al.  Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease , 2014, The Journal of Nuclear Medicine.

[79]  Johannes Kornhuber,et al.  Quantitative modeling of selective lysosomal targeting for drug design , 2008, European Biophysics Journal.

[80]  K. Giacomini,et al.  PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters , 2018, Clinical pharmacology and therapeutics.

[81]  L. Di,et al.  Comparison of Species and Cell-Type Differences in Fraction Unbound of Liver Tissues, Hepatocytes, and Cell Lines , 2018, Drug Metabolism and Disposition.

[82]  Stephen Fowler,et al.  Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[83]  N. Hosten,et al.  Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. , 2012, Radiology.

[84]  J Snoeys,et al.  Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK‐guided drug development approach , 2016, Clinical pharmacology and therapeutics.

[85]  I. Zineh,et al.  Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5 , 2016, Clinical pharmacology and therapeutics.

[86]  Yasuyoshi Watanabe,et al.  Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [11C]Dehydropravastatin in Rats , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[87]  A. Dahan,et al.  Reversal of opioid‐induced respiratory depression by BK‐channel blocker GAL021: A pharmacokinetic‐pharmacodynamic modeling study in healthy volunteers , 2015, Clinical pharmacology and therapeutics.

[88]  X. Chu,et al.  Species differences in drug transporters and implications for translating preclinical findings to humans , 2013, Expert opinion on drug metabolism & toxicology.

[89]  A Rostami-Hodjegan,et al.  Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin , 2014, CPT: pharmacometrics & systems pharmacology.

[90]  X. Chu,et al.  Ontogeny of Hepatic Drug Transporters as Quantified by LC‐MS/MS Proteomics , 2016, Clinical pharmacology and therapeutics.

[91]  Caroline A. Lee,et al.  Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design , 2015, Drug Metabolism and Disposition.

[92]  Bo Feng,et al.  Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach , 2017, Drug Metabolism and Disposition.

[93]  F. Schmidt Meta-Analysis , 2008 .

[94]  Yuichi Sugiyama,et al.  The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model , 2018, Drug Metabolism and Disposition.

[95]  L. Aarons,et al.  Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population‐Modeling Approach , 2014, Clinical pharmacology and therapeutics.

[96]  J. Manro,et al.  Utility of Oatp 1 a / 1 b-Knockout and OATP 1 B 1 / 3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution : Case Studies with Pravastatin , Atorvastatin , Simvastatin , and Carboxydichlorofluorescein s , 2013 .

[97]  Shiew-Mei Huang,et al.  Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP , 2017, Clinical pharmacology and therapeutics.

[98]  V. Lukacova,et al.  Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group , 2015, Clinical pharmacology and therapeutics.

[99]  Justin C. Earp,et al.  Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling , 2016, Drug Metabolism and Disposition.

[100]  P. Vermeersch,et al.  Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients , 2016, European Journal of Clinical Pharmacology.

[101]  Kazuya Maeda,et al.  Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. , 2013, Annual review of pharmacology and toxicology.

[102]  Aleksandra Galetin,et al.  Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes , 2012, Drug Metabolism and Disposition.

[103]  Jan Snoeys,et al.  Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling , 2017, Clinical Pharmacokinetics.

[104]  Aleksandra Galetin,et al.  Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs , 2011, Drug Metabolism and Disposition.

[105]  Yuichi Sugiyama,et al.  Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[106]  James O Lloyd-Smith,et al.  Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. , 2014, The Journal of antimicrobial chemotherapy.

[107]  T. Terasaki,et al.  Blood-Brain Barrier Pharmacoproteomics-Based Reconstruction of the In Vivo Brain Distribution of P-Glycoprotein Substrates in Cynomolgus Monkeys , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[108]  K. Korzekwa,et al.  Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[109]  N Parrott,et al.  Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.

[110]  Yasuyoshi Watanabe,et al.  The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan. , 2011, Molecular pharmaceutics.

[111]  K. Maeda,et al.  Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins , 2017, Drug Metabolism and Disposition.

[112]  Jeffrey P Krise,et al.  Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. , 2007, Journal of pharmaceutical sciences.

[113]  K. Maeda,et al.  Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different In Vitro-In Vivo Extrapolation Approaches. , 2017, Journal of pharmaceutical sciences.

[114]  Hugh A. Barton,et al.  Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human , 2014, Drug Metabolism and Disposition.